Abcuro Raises $66M Series D to Retest Ulviprubart in IBM

Abcuro has closed a $66M Series D led by New Leaf Venture Partners to fund a new study of ulviprubart in patients with less severe inclusion body myositis. Rock Springs Capital joined as a new investor, while a broad group of existing backers returned. The company expects to begin the potentially registrational study in Q4 2026 and report top-line results in 2H 2028.

The financing follows a complicated clinical result. Abcuro's 272-patient Phase 2/3 MUSCLE study missed its primary endpoint and key secondary endpoints in the overall population. In a prespecified subgroup with less severe disease, however, the company reported a non-statistically-significant trend toward slower progression, including roughly 50% slowing relative to placebo across both dose groups.

That distinction is the entire story. The Series D does not finance a proven winner or a commercial launch. It gives Abcuro the capital to test whether patient selection can turn a subgroup signal into evidence strong enough to support a biologics license application.

What Happened

Abcuro announced the financing on August 18, 2026. New Leaf led the round, Rock Springs Capital joined, and returning participants included funds managed by abrdn, Bain Capital Life Sciences, Samsara BioCapital, Redmile Group, Mass General Brigham Ventures, RA Capital Management, Pontifax, Sanofi Ventures, Foresite Capital, NEA, Eurofarma Ventures, Kaitai Capital, Soleus Capital, Nancy Chang, and Shang Bay.

The new capital arrives roughly 18 months after Abcuro raised a $200M Series C to complete the MUSCLE study and prepare for a potential BLA and launch. The clinical outcome changed that route. Instead of moving directly toward a filing, Abcuro is returning to the clinic with a narrower population and another late-stage test.

Why This Round Matters

Biotech financings are often written as confidence votes, but this one is more useful as a test of disciplined conviction. The broad MUSCLE population did not deliver the efficacy result Abcuro needed. The investor case now depends on whether the less-severe subgroup reflects a real treatment effect or a pattern that will disappear under a study designed specifically to examine it.

That is a higher-risk proposition than the funding headline suggests. Subgroup analyses can reveal where a drug may work, especially when prespecified, but they are not substitutes for a successful primary endpoint. Abcuro and its investors are putting $66M behind the next experiment, not declaring the previous one a hidden success.

How Ulviprubart Works

Ulviprubart is an investigational monoclonal antibody that targets killer cell lectin-like receptor G1, or KLRG1, on highly differentiated cytotoxic T cells. Abcuro's thesis is that selectively depleting those cells may reduce the immune-mediated muscle damage associated with inclusion body myositis while sparing other immune-cell populations.

The mechanism is scientifically precise, but the clinical standard is still simple: patients need meaningful preservation of function. IBM progressively affects grip, mobility, swallowing, and independence, and there is no approved pharmacologic treatment. The FDA has granted ulviprubart orphan-drug designation for IBM, but orphan status is a development incentive, not proof of safety, efficacy, or approval.

What the MUSCLE Study Actually Showed

The MUSCLE study evaluated two ulviprubart dose levels against placebo over 76 weeks. Its primary measure was the IBM Functional Rating Scale, with secondary measures assessing areas such as strength and physical performance. The trial missed the primary and key secondary endpoints in the overall population, and that result has to remain visible whenever the subgroup data is discussed.

Abcuro reported that patients with less severe disease showed a trend toward slower progression and that ulviprubart had a favorable safety and tolerability profile compared with placebo. The company-reported 50% slowing figure came from that prespecified subgroup and was not statistically significant. The new trial exists because the result is interesting, not because it is conclusive.

What Investors Are Funding Now

The Series D is funding a second clinical question built around disease stage. Abcuro has been discussing the approach with the FDA and expects the new study to begin in Q4 2026. If the study is positive, the company says it plans to file a BLA, making study design, eligibility criteria, endpoint choice, and statistical power the next set of facts that matter.

CEO Alex Martin is leading the reset, supported by Chief Scientific Advisor and Co-Founder Steven A. Greenberg, whose work helped establish the disease biology behind the company. New Leaf Co-Founder and Managing Director Ron Hunt now represents the lead investor at the point where Abcuro's scientific thesis has to become a narrower clinical one.

The Bigger Biotech Signal

Abcuro's round reflects a familiar tension in drug development: biology can look persuasive long before a study produces a registrational result. The responsible move is neither to bury the endpoint miss nor to dismiss every subgroup finding. It is to design a study that gives the narrower hypothesis a fair chance to fail.

For operators and investors, that is the real lesson in the $66M financing. Capital can buy another trial, but it cannot negotiate with statistics. By 2H 2028, Abcuro expects to know whether the signal in less severe IBM was an early map of efficacy or just a promising shape in incomplete data.